Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mFOLFOX6 + pembrolizumab
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
mFOLFOX6 + pembrolizumab is a combination regimen used primarily in the treatment of gastrointestinal cancers, including colorectal and gastric/gastroesophageal junction (GEJ) adenocarcinoma. The mFOLFOX6 component consists of oxaliplatin, leucovorin, and 5-fluorouracil (5-FU), which together act as cytotoxic chemotherapeutic agents. Oxaliplatin induces DNA crosslinking leading to apoptosis; 5-FU inhibits thymidylate synthase disrupting DNA synthesis; leucovorin enhances the binding of 5-FU to its target enzyme. Pembrolizumab is a humanized monoclonal antibody that targets programmed cell death receptor-1 (PD-1), blocking its interaction with PD-L1 and PD-L2, thereby enhancing T-cell mediated immune responses against tumor cells[3][4][8]. This combination aims to increase immunogenic cell death and improve outcomes by combining direct cytotoxicity with immune checkpoint inhibition[5][8].
- Brand names
- Keytruda
- Other names
- modified FOLFOX6 plus pembrolizumaboxaliplatin-fluorouracil-leucovorin-pembrolizumab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on mFOLFOX6 + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mFOLFOX6 + pembrolizumab.